HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

Q: What FDA designation did HUTCHMED receive for sovleplenib?

Sovleplenib received Orphan Drug Designation for the treatment of primary immune thrombocytopenia. The FDA program covers drugs and biologics intended for rare diseases or conditions affecting fewer than 200,000 people in the United States.

Sovleplenib would be eligible for seven years of US market exclusivity if FDA-approved for the designated indication.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

HUTCHMED (HCM) has received US FDA Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk. Sovleplenib is an oral inhibitor of spleen tyrosine kinase, an enzyme involved in immune signaling.

The designation provides access to development incentives, including qualified clinical-trial tax credits, user fee waivers and specialized FDA guidance. If FDA-approved for the designated indication, sovleplenib would be eligible for 7 years of US market exclusivity. In China, applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia remain under regulatory review, supported by positive pivotal ESLIM-01 and ESLIM-02 trial data, respectively. HUTCHMED retains all worldwide rights to sovleplenib.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

Moderate pointPivotal ESLIM-01 and ESLIM-02 trials provided positive data supporting the respective Chinese applications.
Minor pointSovleplenib received FDA Orphan Drug Designation for primary immune thrombocytopenia.
Minor pointDevelopment incentives include qualified clinical-trial tax credits, user fee waivers and specialized FDA guidance.
Minor point. Forward-looking: it has not happened yet and may not happen.US market exclusivity eligibility is 7 years upon FDA approval for the designated indication.

Negative

Minor pointChinese applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia remain under NMPA regulatory review.

Key Figures

US market exclusivity: 7 years

US market exclusivity: 7 years; Eligible upon FDA approval for the designated indication

Key Terms

orphan drug designation, primary immune thrombocytopenia, syk inhibitor, prescription drug user fee act

4 terms

orphan drug designation regulatory

"FDA has granted Orphan Drug Designation to sovleplenib"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

primary immune thrombocytopenia medical

"for the treatment of primary immune thrombocytopenia"

An autoimmune disorder in which the body's immune system attacks and destroys its own platelets and often interferes with platelet production in the bone marrow, causing a sustained low platelet count (thrombocytopenia) and increased bleeding risk. It is called “primary” when no other underlying condition (such as infection, another autoimmune disease, medication effect, or malignancy) explains the platelet loss; diagnosing it typically requires ruling out those secondary causes. Clinical management and severity vary with platelet count and bleeding symptoms, but the core mechanism is immune‑mediated platelet destruction and impaired platelet production.

syk inhibitor medical

"a novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor"

A SYK inhibitor is a drug that blocks the activity of the enzyme SYK (spleen tyrosine kinase), a molecule that helps immune and certain cancer cells send growth and inflammation signals. By turning down this signaling, the drug can reduce excessive immune reactions or slow tumor growth; for investors, progress, safety, and approval of SYK inhibitors can change a biotech’s value much like a new engine can change a car’s performance, affecting market opportunity and risk.

prescription drug user fee act regulatory

"user fee waivers under the Prescription Drug User Fee Act"

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/28/2026 - 08:00 PM EDT

— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —

— Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition —

— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. Sovleplenib is a novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor.

The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. If approved by the FDA for the designated indication, drugs with Orphan Drug Designation are eligible for 7 years of US market exclusivity upon approval, tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act, and specialized regulatory guidance from the FDA during clinical development.

In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm antibody autoimmune hemolytic anemia are currently under regulatory review by the National Medical Products Administration (NMPA), supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively.

About ITP

ITP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising.¹ ITP is also associated with fatigue (reported in up to 39% of adults with ITP) and impaired quality of life.²^,³^,⁴^,⁵^,⁶ The incidence of primary ITP in adults is 3.3/100,000 adults per year with a prevalence of 9.5 per 100,000 adults.⁷ Based on this prevalence rate, approximately 110,000 patients are estimated to be living with primary ITP in China, in addition to 56,000 patients in the US, Germany, France, Italy, Spain, UK, and Japan. It has been estimated that as many as 145,000 patients are living with chronic ITP in major pharmaceutical markets excluding China.⁸

Adult ITP is a heterogeneous disease that can persist for years, even with best available care, and treatments are infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse.⁹ Thus, there remains a significant population of patients who have limited sensitivity to currently available agents and are in need of new treatments.

As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition represents a promising approach to management of ITP.¹⁰

About Sovleplenib

Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

HUTCHMED currently retains all rights to sovleplenib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of sovleplenib, the further clinical development for sovleplenib, its expectations as to whether any studies on sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of sovleplenib for the treatment of patients with ITP or other indications in China or other jurisdictions, unexpected adverse events or safety issues; the ability of sovleplenib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of sovleplenib for a targeted indication; the sufficiency of funding; HUTCHMED’s ability to successfully develop and commercialize sovleplenib. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com

Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500

Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500

Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

------------------------------------------------------

REFERENCES

¹	Zufferey A, et al. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6(2), 16.
²	McMillan R, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb;83(2):150-4.
³	Snyder CF, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web‑based survey. Curr Med Res Opin. 2008 Oct;24(10):2767-76.
⁴	Doobaree IU, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016 Oct;97(4):321-30.
⁵	Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010 Jul;95(7):1167-75.
⁶	Sarpatwari A, et al. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol. 2010 Oct;151(2):189-91.
⁷	Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.
⁸	Clarivate Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018.
⁹	Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
¹⁰	Crowley MT, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages. J. Exp. Med. 186(7), 1027–1039 (1997).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What FDA designation did HUTCHMED receive for sovleplenib?

Sovleplenib received Orphan Drug Designation for the treatment of primary immune thrombocytopenia. The FDA program covers drugs and biologics intended for rare diseases or conditions affecting fewer than 200,000 people in the United States.

What benefits does FDA Orphan Drug Designation provide for HUTCHMED's sovleplenib?

The designation provides access to development incentives and eligibility for 7 years of US market exclusivity upon FDA approval for the designated indication. Incentives include tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act and specialized FDA guidance during clinical development.

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia